COVID-19 test kits
It seems that after an initial frenzy at the start of the COVID-19 pandemic, when seemingly almost any old test could somehow make it on the market (check out the April news review for comments on quality issues), […]
Blue Steens in Aug-Sep 2020
Check out my latest monthly review! It showcases Blue Steens’ latest posts, some news from biopharma & medtech as well as interesting events I have attended or noticed. At a glance In terms of COVID-19, test kits […]
Plasma vs virus
Convalescent plasma (CP) therapy gained FDA emergency use authorisation (EUA) in August. It appears that this is surrounded by some controversy and suspicion of politicisation. Without getting anywhere near politics here, let’s not forget that health agencies’ […]
It’s not an immunity passport
I have had discussions lately about the perception that an immunity passport is the same as a vaccination passport. This is not so. The choice of words matters! Let’s explore this from a basic immunological perspective.
Blue Steens in June 2020
Check out my latest monthly review! It showcases Blue Steens’ latest posts, some news from biopharma & medtech as well as interesting events I have attended or noticed. At a glance In terms of COVID-19, we’ve seen […]
Daclizumab – Manipulating the immune system in unexpected ways
Daclizumab, marketed as Zinbryta, was approved for the treatment of relapsing-remitting multiple sclerosis (MS) in the USA and Europe in summer 2016. Daclizumab has shown superior efficacy when compared to placebo and a standard treatment (AVONEX®, interferon beta-1a) and is believed to […]